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 Abstract 
The Translational Research Working Group (TRWG) was created as a national initiative 
to evaluate the current status of NCI’s investment in translational research and envision 
its future. The TRWG conceptualized translational research as a set of six developmental 
processes or pathways focused on various clinical goals. One of those pathways describes 
the development of biospecimen-based assays that utilize biomarkers for the detection, 
diagnosis, prognosis, and assessment of response to cancer treatment. The biospecimen-
based assessment modality (BM) pathway was conceived not as comprehensive 
description of the corresponding real-world processes, but rather as a tool designed to 
facilitate movement of a candidate assay through the translational process to the point 
where it can be handed off for definitive clinical testing.  This paper introduces the 
pathway in the context of prior work and discusses key challenges associated with the 
biomarker development process in light of the pathway. 
 
Introduction 
Molecular biomarkers are at the heart of our aspirations for a new era of cancer 
prevention and treatment.  Novel biomarkers offer the potential for improved 
management of the disease at every point from screening and detection, through 
diagnosis, staging and prognosis, to assessment of treatment response.   
 
Large-scale assays and bibliometric searches have identified hundreds of candidate 
biomarkers for various cancers.  To date, however, the successful translation of a 
candidate biomarker from discovery to routine clinical application remains relatively rare  
 (1).  Even as the research community wrestles with the methodologic challenges of 
biomarker development, conditions for bringing biomarker-based tests to market are 
becoming more stringent, with both regulators and payors moving to apply more rigorous 
standards for analytic and clinical validation.  To assure that scarce resources are invested 
wisely, there is an urgent need to develop and consistently apply more systematic and 
effective approaches to the development of cancer biomarkers.  
 
The combination of clinical need, scientific promise and methodological challenge made 
biomarker development a focus of the TRWG.  As with other key areas of cancer 
translational research, the TRWG sketched out a flowchart of steps in biomarker 
translational research to facilitate identification of challenges and bottlenecks and 
stimulate and focus discussion about how best to address them in any given 
developmental project.  An introduction and overview of the TRWG Developmental 
Pathways to Clinical Goals is found in Hawk et al (2).  This paper is intended to explain 
the purpose of the BM pathway depicted in Figure 1 in the context of prior efforts to 
systematize the approach to biomarker development, and to highlight key aspects of the 
process that warrant special attention. 
 
Insights from Previous Work 
In drafting the developmental pathway, the TRWG followed the pioneering work of Pepe 
et al, who addressed the phases of development of biomarker-based screening tools for 
early detection of cancer in a seminal article (3).   Pepe et al defined these phases as 
follows, by analogy with the process by which new drugs are developed: 
 • Phase 1, “Preclinical Exploratory”, in which promising directions are identified 
• Phase 2, “Clinical Assay and Validation”, in which the ability of the clinical assay 
to detect established disease is demonstrated 
• Phase 3, “Retrospective Longitudinal”, in which the ability of a biomarker to 
detect disease before it becomes clinically evident is demonstrated, and rule for 
judging a result as “positive” is defined 
• Phase 4, “Prospective Screening”, in which the extent and characteristics of 
disease detected by the test and the false referral rate are identified 
• Phase 5, “Cancer Control”, in which the impact of screening on reducing the 
burden of disease on the population is identified 
In describing these phases, Pepe et al focus especially on the question of what kinds of 
evidence are needed to establish the clinical validity and utility of a new biomarker.   
 
The TRWG also gained important insights from a key element of NCI’s current 
biomarker research portfolio, the Early Detection Research Network (EDRN)1.  In the 
context of the TRWG’s work, EDRN is noteworthy for taking a systems view of the 
translational research process, defining key functional elements and implementing them 
in an explicitly structured and choreographed way that reflects and addresses the 
evidentiary framework specified by Pepe et al.  The EDRN approach recognizes that the 
culture and working methods of the fundamental science laboratories from which 
                                                 
1 EDRN is a program of the National Cancer Institute’s Division of Cancer Prevention.  EDRN grantees 
participate in cross-disciplinary, collaborative research focused on the goal of creating validated biomarkers 
for early cancer or cancer risk, that are ready for large-scale clinical testing.  Early Detection Research 
Network [homepage on the Internet].  Rockville, MD: National Cancer Institute [cited 2008 Jul 2].  
Available from:  http://edrn.nci.nih.gov/. 
 
 biomarker candidates typically emerge are not well-matched to the requirements of 
product development and of analytical and clinical validation, and offers an alternative 
path better suited to the task. 
 
Building on these efforts, the TRWG drafted a Developmental Pathway for Biospecimen-
Based Risk Assessment Devices that lays out the biomarker translational research process 
from a systems perspective, describing it in terms of key activities and decision points 
along the path from concept through assay development to clinical testing.  Compared to 
the frameworks created by the earlier efforts, the TRWG developmental pathway differs 
in important respects.  Its focus on the phases of development is narrower, excluding 
fundamental discovery research to concentrate on the process by which emerging 
concepts are translated into a tangible form ready for definitive clinical testing.  Thus, the 
TRWG biospecimen/biomarker developmental pathway overlaps with Phases 2 through 4 
of the schema of Pepe et al.  However, while Pepe et al use the phases as a framework 
for clarifying the kinds of evidence needed to establish the clinical validity and utility of 
a new biomarker, the TRWG developmental pathway parses the development process 
from the perspective of a scientist-manager, applying a programmatic and operational 
perspective to the systematic assessment of translational research activity with the 
objective of enhancing the efficiency and effectiveness of that activity.  In addition, 
compared to both the analysis of Pepe et al and the programmatic focus of the EDRN, the 
TRWG developmental pathway encompasses a broader range of biomarker applications, 
extending beyond screening and early detection to encompass uses in the therapeutic 
setting as well. 
  
Validation:  the Central Challenge 
The biomarker pathway is distinctive in that the greatest challenges associated with 
translation revolve around not around creation of the modality (that is, development of 
the practical laboratory procedures or kits needed to implement tests based on the 
marker), but rather around its validation.  The TRWG used the term validation broadly, to 
cover all of the many different activities designed to verify that the characteristics of the 
modality are as expected or desired.  With respect to biomarker-based assessment 
modalities this includes especially analytic validity – “a test’s ability to measure the 
analyte or genotype of interest accurately and reliably” and clinical validity – “a test’s 
ability to detect or predict the associated disorder (phenotype)”.2 
 
Of these two key dimensions of performance, assuring clinical validity poses the greatest 
conceptual and methodological challenges throughout the developmental pathway, from 
credentialing of the initial discovery through clinical trials.  Success requires rigorous 
adherence to careful study design and valid statistical methodology to avoid the trap of 
spurious correlation. 
 
Important methodological considerations that have often not been addressed in the past in 
the development of biomarker-based diagnostics include attention to data accuracy, 
                                                 
2 Secretary’s Advisory Committee on Genetics, Health and Society.  U.S. System of Oversight of Genetic 
Testing: A Response to the Charge of the Secretary of Health and Human Services.  Department of Health 
and Human Services; 2008 Apr [cited 2008 Jul 5].  Available from:  
http://www4.od.nih.gov/oba/sacghs/reports/SACGHS_oversight_report.pdf 
 
 reproducibility, or standardization beyond the lab in which the markers were discovered;  
blinding of the lab researchers who perform the assays with respect to the status of the 
samples (whether it is a case or a control, whether they are replicates from the same 
specimen); and randomization of samples and their replicates to the assay allocations 
(e.g., spots on the chip, chips, assay dates, etc).  Evaluation of cancer therapeutic 
modalities is usually conducted via multi-center clinical trials operating under clearly 
specified and strictly enforced investigational protocols; the same discipline needs to be 
applied to biomarker validation.   
 
The biostatistical challenges of validating associations and assessing their predictive 
value in real-world populations are, if anything, more subtle and difficult than those faced 
in typical randomized trials of therapeutics (4). In assessing the robustness of the 
correlation with the clinical phenomena of interest that define the potential value of a 
biomarker, it is essential that successive rounds of testing be done using truly 
independent sample sets, and that the specificity, sensitivity and predictive value of the 
assay be quantified in study populations where the prevalence of the marker reflects what 
is likely to be observed in clinical practice.  Development of profile-based tests 
introduces a new layer of methodological traps for the unwary.  Seemingly small errors in 
the specification of statistical models, failure to replicate results using truly independent 
sample sets or any bias introduced by failure to incorporate careful blinding and 
randomization will have an even larger impact. 
 
Credentialing  
 During the credentialing phase of the BM pathway, the questions of clinical validation, 
clinical need, and feasibility are addressed.   Is available exploratory data sufficiently 
convincing to justify the expenditure of resources in a focused effort to develop a 
practical assay?  In sifting through the vast amounts of available information to evaluate 
and prioritize biomarker candidates for translation, the key requirement in addition to 
valid statistical methodology is care in identifying clinical scenarios in which the 
availability of a robust biomarker is likely to provide meaningful clinical benefit by 
enabling strategies for prevention or treatment that are measurably more effective.   
 
 
Supporting Tools 
A key hurdle that biomarker developers face is access to a sufficient quantity of properly 
preserved, clinically relevant, well annotated biospecimens.  As an example, development 
of the Oncotype DX breast cancer assay, one of the first of a new generation of 
genomics-based tests to reach the market, relied in large part on biospecimens from 
National Surgical Adjuvant Breast and Bowel Project studies (5-6).  In the absence of an 
established network of biospecimen repositories addressing a range of tumor types, 
successful translation of candidate biomarkers is subject to the chance availability of the 
required samples. 
 
The development of tests based on profiles of markers underscores the importance of 
systematically cataloged knowledge on a broad range of markers, even those that do not 
appear to demonstrate a robust association with clinical phenomena of interest when 
 assessed individually. 
 
Creation of Modality 
Researchers are pursuing a wide range of genomic, proteomic and metabolomic species 
and analytic methods for use as biomarker-based assessment modalities; each method 
poses its own distinct challenges and potential pitfalls in the areas of implementation 
requirements, sensitivity, specificity, reproducibility, and interpretation. Particularly 
where the analytic approaches to be applied are novel, special attention is required to 
standardization of methods and reproducibility of results, at all stages from creation of 
the modality and proof of concept in the laboratory through implementation of products 
or protocols intended for definitive clinical trials and implementation in routine clinical 
settings. 
 
Preclinical Development 
Regulatory Considerations 
To be successful, the development process must be organized to cope effectively with the 
regulatory system under which diagnostic products are brought to market in the United 
States. 
 
Two parallel regulatory regimes are involved in the regulation of in vitro diagnostics – 
clinical laboratories are regulated by the Centers for Medicare and Medicaid Services 
 (CMS) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA),3 while 
medical devices, including in vitro diagnostic products, are regulated by the Food and 
Drug Administration (FDA).4 For a number of years a status quo prevailed, under which 
“home brew” tests assembled by individual laboratories from general-purpose “analyte-
specific reagents” (ASRs) were regulated for analytic validity and proficiency in 
laboratory implementation under CLIA, while “kits”, or complete, packaged tests 
marketed to laboratories by a manufacturer, were regulated by FDA, with a somewhat 
more stringent requirement for evidence of clinical validity and utility, as well as 
requirements for quality control in manufacture.   
 
As a general matter, laboratory procedures used to generate data in non-clinical studies 
that will be used to support a product submission to FDA must meet standards for Good 
Laboratory Practices (GLP);5 manufacturing processes for test components must meet 
standards of composition, stability and consistency, as specified by Good Manufacturing 
Practices (GMP);6 and well-defined, standardized protocols must be created for use of the 
                                                 
3 Centers for Medicare and Medicaid Services [homepage on the Internet].  Baltimore, MD:  Centers for 
Medicare and Medicaid Services [updated 2008 May 8;  cited 2008 July 2]. Clinical Laboratory 
Improvement Amendments (CLIA).  Available from:  http://www.cms.hhs.gov/CLIA/. 
 
4 Food and Drug Administration [homepage on the Internet].  Rockville, MD:  Food and Drug 
Administration [cited 2008 Jul 2].  Office of Regulatory Affairs, Bioresearch Monitoring Good Laboratory 
Practices.  Available from:  http://www.fda.gov/ora/compliance_ref/bimo/glp/default.htm. 
 
5 Food and Drug Administration [homepage on the Internet].  Rockville, MD:  Food and Drug 
Administration [cited 2008 Jul 2].  Office of Regulatory Affairs, Bioresearch Monitoring Good Laboratory 
Practices.  Available from:  http://www.fda.gov/ora/compliance_ref/bimo/glp/default.htm. 
 
6 Food and Drug Administration [homepage on the Internet].  Rockville, MD:  Food and Drug 
Administration [updated 2004 Jan 28;  cited 2008 Jul 2].  Center for Devices and Radiological Health, 
Good Manufacturing Practices (GMP) / Quality System (QS) Regulation.  Available from:  
http://www.fda.gov/CDRH/DEVADVICE/32.html. 
 
 assay in clinical laboratories and for quality assurance and verification of proficiency in 
such routine use. 
 
With rapid innovation in genomic technologies leading to the emergence of new assays 
based on the association of genomic biomarkers with clinical conditions, regulators have 
begun to focus greater attention on the adequacy of existing approaches to assure the 
safety and efficacy of these new products.  As a result, the regulatory system for in vitro 
diagnostic tests is in transition. 
 
A key milestone in this transition has been FDA’s recent release of a draft guidance on 
multivariate index assays, presenting its views of the technical issues involved and 
explaining its proposed approach to regulating these new tests7.  This draft guidance has 
been the focus of some controversy, and certain elements of the FDA’s proposed 
approach have not been finalized as of this writing.  However, the strategy adopted by 
some developers – to implement new genomics-based diagnostic tests as centralized 
laboratory services in order to bring then to market under CLIA rather than more 
stringent FDA regulation – is likely to be restricted or eliminated.  
 
Changes in the regulatory regime for in vitro diagnostics will reinforce the scientific and 
clinical imperative to define and adhere consistently to more robust standards for both 
analytic and clinical validation.  The developmental pathway reflects this more rigorous 
                                                 
7 Draft guidance for industry, clinical laboratories, and FDA staff: in vitro diagnostic multivariate index 
arrays, July 26, 2007.  Rockville, MD:  Food and Drug Administration [cited 2008 Jul 2].  Available at 
http://www.fda.gov/cdrh/oivd/guidance/1610.pdf. 
 
 approach, conceptualizing translational research on biomarkers as extending through 
validation in prospective clinical studies. 
 
Implications of Trends in Insurance Coverage for New Clinical Products and 
Services 
With respect to insurance coverage of new clinical products and services, there are two 
distinctive aspects of diagnostic or screening tests that increase concerns among payors 
about both efficacy and appropriate use.  First, medical officers at the major health 
insurers are aware of the methodological challenges of developing robust and valid 
biomarkers and the risk that apparent correlations will prove illusory on more rigorous 
analysis.  A fairly high threshold of skepticism is usually applied to claimed advances in 
this field, because of concern that faulty tests will reach the market, consuming resources 
unproductively or even placing patients at risk of inappropriate care and adverse 
outcomes.  Payors also have strong concerns that the availability of a new, expensive 
assay will lead to a wave of costly, inappropriate usage, because of a widespread 
perception that diagnostic tests, especially those based on blood samples or on non-
invasive imaging, impose relatively little risk for a patient compared to therapeutic 
interventions. 
  
The consequence of these concerns is that payors demand more extensive data on 
diagnostic tests than is required to gain FDA approval, in order to validate their clinical 
benefits in real-world practice.8  The implication for biomarker developers is that 
                                                 
8 As an example from oncology, at the time of writing neither Aetna nor Cigna covers the Invader UGT1A1 
 rigorous attention to clinical value is required throughout the development process.  
Reliable detection of a biomarker – analytic validity – is not by itself sufficient to gain 
market acceptance for a new product. 
 
Coupling Biomarkers with Treatments 
Interactions between this developmental pathway and the developmental pathway for 
new targeted therapeutic agents must be considered as well.  The role of diagnostic tests 
for HER2 overexpression in defining the population of metastatic breast cancer patients 
for whom trastuzumab is an effective treatment is a model for targeted agents of the 
future.  However, development of such diagnostic/therapeutic pairs will likely be more 
effective – and more cost-effective – when the parallel development paths are 
coordinated from earlier in the development process than was the case with HER2 and 
trastuzumab. 
 
Such coordination can be quite complex, with logistical challenges further exacerbated by 
the fact that, in most cases, the diagnostic and the therapeutic are being developed by 
different companies or organizations.  The FDA has issued a draft concept paper on drug-
diagnostic co-development that addresses aspects of the co-development process, with 
the objective of facilitating a shared understanding with academia and industry of 
                                                                                                                                                 
molecular assay used to determine irinotecan dosing.  Despite gaining FDA approval, it is considered 
“experimental and investigational because its clinical value has not been established.”  Aetna Clinical 
Policy Bulletin number 0715, Pharmacogenetic Testing, last review 04/25/2008, accessed June 26, 2008 at 
http://www.aetna.com/cpb/medical/data/700_799/0715.html; CIGNA HealthCare Coverage Position 
number 0381, Drug Metabolizing Enzyme Genotyping Systems, revised 6/15/2008, accessed June 26, 2008 
at 
http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0381_cove
ragepositioncriteria_AmpliChip.pdf. 
 
 approaches that are likely to produce results sufficiently robust to support regulatory 
decision making9.  The TRWG developmental pathways can facilitate coordination by 
specifying developmental steps and clarifying dependencies between the developmental 
steps for therapeutics and for their associated biomarkers. 
 
Example of the Use of the Biospecimen-based Assessment Modality  
Pathway 
Although the developmental pathway was created by the TRWG and thus has not been 
used to guide previous development efforts, it is instructive to review prior efforts in light 
of the pathway. 
 
The development of a fluorescent in-situ hybridization (FISH) assay in urine samples for 
the detection of bladder cancer followed the biomarkers pathway closely.  The technique 
was originally developed at Lawrence Livermore National Laboratory (7), and academic 
researchers performed the fundamental research that indicated the FISH technology could 
be applied to early detection of bladder cancer (8).  Vysis Inc. provided the supporting 
tool of a reproducible assay by further developing the FISH technology for use in clinical 
tests and demonstrated to the FDA that assays based on FISH were sufficiently robust 
and reproducible to be used for clinical purposes.  Vysis credentialed the use of FISH for 
early detection of bladder cancer as a commercial target based upon the combination of 
clinical need (existing tests had limited sensitivity/specificity) and the assessment that 
                                                 
9 Drug-diagnostic co-development concept paper (draft), April 2005.  Rockville, MD:  Food and Drug 
Administration [cited 2008 Jul 2].  Available at http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf. 
 
 Vysis’s FISH technology could improve upon those tests (9).  The company collaborated 
with the University of Basel and Mayo Clinic to obtain the required supporting tools of 
samples and clinical data sets.  They developed the modality by validating the technology 
using these data sets and proceeded through the preclinical development and clinical trial 
steps by pursuing large-scale prospective studies.  FDA approval for the UroVysion test 
was granted in 2005 10. 
 
Looking to the Future  
The value of the developmental pathway as a tool for project and program planning, for 
training and for heightening general awareness of the optimal approach to biomarker 
development can be enhanced through further development of the pathway to reflect the 
activities, decision points and interactions associated with the regulatory process and with 
co-development of drugs and therapeutics. Continued investment in strong analytical 
technology, informatics, statistics, epidemiology and in biosample management will pay 
dividends through high quality data that will meet regulatory requirements.  
 
Review of the developmental pathway reminds us once more of the importance of NCI’s 
efforts to develop biospecimen repositories as well as management approaches for 
prioritizing and facilitating access to these essential resources. 
 
Finally, academic culture emphasizes individual achievement over collaborative work.  
                                                 
10 UroVysion Bladder Cancer Kit – Summary of Safety and Effectiveness Data.  Rockville, MD:  Food and 
Drug Administration [cited 2008 Jul 2].  Available at:  http://www.fda.gov/cdrh/pdf3/p030052b.pdf. 
 
 However, realizing the full potential of the nation’s investment in cancer research 
requires collaboration that crosses disciplinary boundaries and integrates complementary 
activities in government, academia and industry to achieve priority objectives.  We must 
find ways to incentivize the kind of creativity and intellectual leadership that not only 
creates new concepts but also advances them to fruition. 
 
Conclusion 
Despite the central role of biomarkers in current thinking about cancer screening, 
diagnosis and therapeutics, progress in bringing biomarker-based assessment modalities 
to the clinic has been disappointing.  The substantial challenges posed by biomarker 
development can be met only through rigorous adherence to high methodological 
standards and close attention to the requirements of regulators and payors.  The BM 
Pathway clarifies the elements of the development process, provides a framework for 
understanding key scientific and regulatory challenges in the development process, and 
facilitates coordination of the diverse, cross-disciplinary efforts required to meet those 
challenges. 
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 Figure 1:  Biospecimen-based Assessment Modality Pathway.   
The BM pathway is depicted as a flowchart, a schematic process representation widely 
used in engineering.  The rounded rectangle at the top indicates the origin of the process.  
Square-cornered rectangles indicate activity steps.  Conditional tests, or decision steps, 
are represented as diamonds.  Unidirectional arrows indicate the direction of the activity 
sequence, and the direction of transfer of supporting tools from their parallel 
development paths to the main path of modality development. The three diamonds in the 
initial steps of the pathway (blue) are decisions required to proceed through the pathway 
and represent the credentialing step.  Subsequent steps include the development of 
supporting tools (red), the creation of the modality (green), preclinical development 
(purple) and early stage clinical trials (yellow). For each activity or decision point, it is 
understood that there are many more variations that can occur, and that not all steps may 
occur in each instance. The pathway dies not address the ways in which insights gained 
from late-stage clinical trials can influence the development process. Biospecimen-based 
assessment devices can be used for screening, early detection, diagnosis, prediction, 
prognosis, or response assessment. The pathways are conceived not as comprehensive 
descriptions of the corresponding real-world processes but as tools designed to serve 
specific purposes, including research program and project management, coordination of 
research efforts, and professional and lay education and communication. 
 
 
 
 
 
 TEXT BOX:  KEY POINTS 
 
• The BM Pathway heightens awareness of the elements of the development path 
and provides a framework for understanding key scientific and regulatory 
challenges in bringing new biomarker-based assessment modalities to the clinic. 
• The BM Pathway highlights the central role of validation throughout the 
development of biomarker-based assessment modalities. 
• The BM Pathway highlights the need for biospecimen repositories and other 
supporting tools. 
 
• The BM Pathway can lead to improved communication and effective 
choreography of the relationships between academia, government, and industry 
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